The Effect of Methylprednisolone, Interferon Beta and Glatiramer Acetate Treatment on the Levels of Leptin, Adiponectin and Resistin in Multiple Sclerosis Patients

Sławomir Michalak1,2*, Łukasz Jernas3*, Ewa Wysocka4, Krystyna Osztynowicz1, Elżbieta Tokarz-Kupczyk1, Halina Wylgadalska-Jernas3 and Wojciech Kozubska2

1Department of Neurochemistry and Neuropathology, Poznan University of Medical Sciences, 60-355 Poznan, Przybyszewskiego str. 49, Poland
2Neuroimmunological Unit, Polish Academy of Sciences, 60-355 Poznan, Przybyszewskiego str. 49, Poland
3Department of Clinical Biochemistry and Laboratory Medicine, Chair of Chemistry and Clinical Biochemistry, Poznan University of Medical Sciences, Poland

Abstract

Objective: Adipocytokines are cytokine-like mediators that link adipose tissue function with inflammatory and autoimmune processes, and have a suggested role in the pathogenesis of multiple sclerosis (MS). The aim of this study was to analyze the effects of methylprednisolone, interferon-1b (INF) and glatiramer acetate (GA) on leptin, resistin, and adiponectin concentrations in relapsing-remitting MS (RRMS) patients.

Methods: The study included 154 RRMS patients who were hospitalized in the Department of Neurology, Poznan University of Medical Sciences. The comparison group included 31 patients with myasthenia gravis (MG) and 39 healthy controls. Serum levels of leptin, adiponectin, and resistin were evaluated before treatment initiation. In the RRMS patients treated with methylprednisolone, adipocytokine evaluation was performed one day after the therapy. Patients treated with INF or GA were evaluated at 1 month and 6 months. Routine neurological examination and expanded disability status scale (EDSS) scoring were performed, and MRI scans were analyzed for the localization of demyelinating plaques. Body mass index, glycemia, and insulin levels were evaluated and homeostatic model assessment insulin resistance index (HOMA-IR) was calculated.

Results: Adiponectin and resistin levels in RRMS and MG patients were increased compared to controls, but adiponectin levels were lower in RRMS than MG patients. INF treatment caused a significant, time-dependent effect on resistin concentration. GA administration influenced only resistin concentration as a long-term effect. No relationship between adipocytokines and metabolic status or insulin resistance was found.

Conclusions: We identify resistin as the most important adipocytokine associated with RRMS. Its concentrations are reduced by first line immunomodulatory treatment, which produces a milieu of beneficial inflammatory and metabolic processes. On the other hand, the routine treatment of MS relapses with methylprednisolone induces harmful metabolic and inflammatory effects that may be mediated by elevated leptin levels.

Keywords: Leptin; Resistin; Adiponectin; Multiple sclerosis; Methylprednisolone; Interferon-1b; Glatiramer acetate

Introduction

Adipocytokines are cytokine-like mediators produced by adipose tissue and are involved in inflammation, immune response, and metabolism. Leptin, adiponectin, and resistin belong to the most abundant family of adipocytokines that link adipose tissue function with inflammatory and autoimmune processes [1]. Leptin is recognized as an immunomediator. On the one hand, it controls the homeostatic balance between food intake and energy expenditure, its concentration increases during fat accumulation and decreases during fasting. The concentration of leptin in the sera of obese individuals is increased, indicating these individuals have leptin-resistance [2]. Additionally, its reduction contributes to insulin resistance in animal models [3]. On the other hand, leptin acts as a pro-inflammatory adipocytokine by stimulating the production of interleukin 6 (IL-6), tumor necrosis factor alpha (TNF-α) and interleukin 12 (IL-12) in monocytes and macrophages [4], and inhibiting the production of anti-inflammatory cytokines, including interleukin 4 (IL-4), in CD4+ T cells [5]. Resistin is also a pro-inflammatory adipocytokine that is produced by adipocytes, macrophages, and mononuclear cells. It stimulates the production of pro-inflammatory cytokines like TNF-α and IL-12 [6]. Moreover, resistin regulates the immune response by influencing regulatory T cells. It inhibits the expression of interferon regulatory factor (IRF)-1 and related cytokines, IL-6, interleukin 23p19 (IL-23p19) and interleukin 12p40 (IL-12p40) in dendritic cells, which also mediate the upregulation of Forkhead box P3 (FoxP3) expression in CD4+ T by resistin [7]. The decreased insulin-mediated downregulation of gluconeogenesis and increased glycolysis [8] and decrease in insulin-stimulated phosphorylation of key regulatory liver enzymes, all metabolic effects caused by resistin [9], leads to hepatic insulin resistance. In contrast to leptin and resistin, adiponectin acts as an anti-inflammatory adipocytokine [1], and also promotes insulin sensitivity.

*Corresponding author: Sławomir Michalak, Department of Neurochemistry and Neuropathology, Poznan University of Medical Sciences, 60-355 Poznan, Przybyszewskiego str. 49, Poland, Tel: +48 61 8691 443; Fax: +48 61 8691 444; E-mail: swam622@gmail.com

Received December 21, 2013; Accepted February 19, 2014; Published February 27, 2014


Copyright: © 2014 Michalak S, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
in skeletal muscles, in the liver and adipose tissue [10]. However, it has also been shown to increase the production of interleukin 8 (IL-8) in human macrophages stimulated by lipopolysaccharides [11].

The observation that adipocytokines are involved in inflammatory and immune processes has led to increased interest over the last few years regarding their role in multiple sclerosis (MS). Leptin has been suggested as a link between immune tolerance, metabolic state and autoimmunity. It is involved in the development of experimental autoimmune encephalomyelitis (EAE) [12,13] and the elimination or neutralization of leptin limits an autoimmune response in the course of EAE by reducing delayed-type hypersensitivity against proteolipid protein, CD4+ T cell hypersensiveness against myelin antigens, and increasing IL-4 and IL-10 production and the number of regulatory FoxP3 CD4+ T cells [14].

Elevated resistin concentrations were found in patients with relapsing-remitting multiple sclerosis (RRMS) compared to healthy controls [15]. Moreover resistin and TNF-α concentrations were higher in patients monozygous for GG with the rs1862513 genotype who had multiple sclerosis [16]. Thus, resistin gene polymorphisms contribute to an increased risk for MS.

Adiponectin concentrations in cerebrospinal fluid were increased in MS individuals compared to their non-MS twins and did not correlate with plasma concentrations, suggesting intrathecal production [17]. Reports on adiponectin concentration in MS patients compared to controls have demonstrated equivocal results. A lowering in adiponectin concentration was observed in MS patients [15]. However, recently, an elevated adiponectin concentration was reported in the context of increased risk for cardiovascular diseases in MS patients, and a negative correlation between small HDL-c and adiponectin concentration was found [18].

Limited data exist on the effect of immunomodulatory treatment on adipocytokines levels in MS patients [19,20].

The aim of our study was to analyze the effect that the routine treatment of relapse with methylprednisolone and first line immunomodulatory drugs (interferon-1b and glatiramer acetate) had on the leptin, resistin and adiponectin concentrations in RRMS patients. We undertook an analysis of the relationship between insulin resistance and the concentration of adipocytokines in RRMS patients. The inclusion of myasthenia gravis patients in addition to healthy controls was justified by the need to compare the effects another autoimmune disorder has on the adipocytokine profile.

Materials and Methods

The study included 154 patients with relapsing-remitting multiple sclerosis (RRMS) hospitalized in the Department of Neurology at Poznan University of Medical Sciences, Poland and patients participating in an immunomodulatory treatment program being carried out for 2 years by the National Health Fund. Among RRMS patients, 31 were treatment naïve, 52 who had a relapse were treated with standard [21] intravenous methylprednisolone (1.0 g i.v. for 5 days), 55 underwent interferon beta-1b (250 μg subcutaneously every other day) and 16 glatiramer acetate (subcutaneously 20 mg / day) treatment, respectively. In the RRMS group, 15 patients (9.7%) had associated diabetes.

The comparison group consisted 31 myasthenic patients (11 who had diabetes [35%], 2 who had RRMS) included into the study before initiation of any treatment.

Exclusion criteria were: diagnosis of autoimmune disorders (e.g. lupus and other connective tissue disorders, acute disseminated encephalomyelitis, neuromyelitis optica, Hashimoto thyroiditis, celiac disease, gastrointestinal autoimmune diseases), sarcoidosis, central nervous system infections or current administration, or history, of immunosuppression.

The control group consisted of 39 age matched healthy volunteers not exposed to any treatment.

The levels of leptin, adiponectin, and resistin were evaluated in all participants of the study before the initiation of treatment by means of an ELISA (DRG Medtek, USA). In RRMS patients with relapse who were treated with methylprednisolone, the second adipocytokine evaluation was performed one day after the therapy. In patients treated with interferon-1b or glatiramer acetate the time points for adipocytokine evaluation were after 1 month and 6 months of the treatment. Routine neurological examination and EDSS scoring were performed in all RRMS patients at the baseline. Neurological examination and EDSS score were next repeated at the 1st and 6th month of the treatment and during relapse.

Magnetic resonance imaging (MRI) scans were analyzed for the localization of demyelinating plaques (supratentorial, infratentorial, spinal cord).

The metabolic aspects analyzed in all participants included the following: body mass index (BMI), glycemia, insulin levels (by means of ELISA, BioSource), and insulin resistance index HOMA calculated by the following formula:

HOMA-IR (insulin-resistance index)=\[\text{insulin (μU/ml) } \times \text{glycemia (mg/dl)}\] /405.

Statistical analysis was performed with the use of a licensed version of MedCalc 12.7.5.0 (64 bit) software. First, the distribution of results was analyzed with the D’Agostino-Pearson test. The variables that had a normal distribution were expressed as mean ± SD and tested with an F test; the variables that had a non-Gaussian distribution were expressed as median and interquartile range and analyzed with the Mann-Whitney test. Dependent variables represented by the levels of adipocytokines during treatment with methylprednisolone, interferon-1b and glatiramer acetate were compared with the Kruskal-Wallis test.

The study protocol was accepted by the Ethics Committee of Poznan University of Medical Sciences and each participant recruited gave informed consent.

Results

We did not find any significant differences in age, BMI, glycemia, or insulin levels between RRMS patients, myasthenia gravis patients, and controls (Table 1).

Adiponectin and resistin levels in RRMS and myasthenia gravis patients were increased compared to controls (Table 1); moreover, in RRMS patients, adiponectin levels were lower than in those with myasthenia gravis (Table 1). Resistin concentration correlated positively with the duration of RRMS (r= 0.186; P=0.0456). There were no differences (P=0.05) in leptin, adiponectin, or resistin concentrations between non-diabetic and diabetic RRMS patients (Table 2).

Insulin resistance represented by HOMA-IR was found only in diabetic RRMS patients (Figure 1). There were no differences in HOMA-IR between RRMS, MG patients, and controls, nor between non-diabetic and diabetic RRMS and MG patients (Table 1).
Intravenous methylprednisolone in RRMS with relapse caused an increase (P=0.001) in leptin concentration (14.10; 6.38-20.14 vs. 6.95; 3.21 to 14.39 ng/mL; median, interquartile range) and had no effect on adiponectin (8.21; 4.16-2700.88 vs. 944.69; 5.11-2523.85 ng/mL, P=0.6674) and resistin concentration (10.03; 8.16-14.76 vs. 9.42; 6.89-12.92 ng/mL, P=0.1498). Resistin concentration correlated positively with HOMA-IR insulin resistance index (Spearman’s r=0.351, P=0.0386) in methylprednisolone treated patients.

Interferon-1b treatment caused a significant (P<0.0001) time-dependent effect on resistin concentration and did not modify leptin (P=0.9633) or adiponectin (P=0.3338) concentrations (Table 3). There was no relation between EDSS score and adipocytokines concentrations in interferon 1b treated patients during the 6 months of observation.

Glatiramer acetate treatment influenced only resistin concentration after 6 months, and showed no effect on either adiponectin (P=0.9911) or leptin (P=0.5951) concentrations (Table 4). In the glatiramer acetate group at baseline we observed differences (P=0.0256) in resistin concentration between patients who received an EDSS score of 0 (57.58; 48.86-79.11 ng/mL, median interquartile range), 1 (32.52; 28.60-36.02 ng/mL) and 1.5 (66.58; 54.2-123.70 ng/mL). Further on during the treatment there was no relationship between EDSS score and adipocytokines concentration.

We did not observe a correlation between adipocytokines concentrations and the number of relapses during interferon-1b and glatiramer acetate treatment, or before the treatment initiation. Moreover, we did not find any relationship between the localization of demyelinating plaques (supratentorial, infratentorial, spinal cord) in MRI scans and the concentration of adipocytokines.

Adipocytokine concentrations did not correlate with the HOMA-IR insulin resistance index in interferon-1b and glatiramer acetate treated patients.

**Discussion**

In our study we found that neurological autoimmune disorders are associated with increased concentrations of adipocytokines with a particular significance for resistin in RRMS patients. Routine methylprednisolone treatment induced a harmful effect that led to an increase in leptin levels. First line immunomodulatory treatment by reducing resistin concentration limits the immune response mediated by adipocytokines in RRMS patients.

In the age, BMI, and insulin resistance balanced groups that were involved in our study, we observed increased concentrations of resistin and adiponectin in RRMS and MG patients.

To the best of our knowledge, this is the first study on adipocytokines in RRMS that considers the metabolic and insulin resistance status of the analyzed subjects. Thus, we may suggest that the observed changes in
The effects of interferon 1b treatment on adipocytokines concentrations.

| Table 3: The effects of interferon 1b treatment on adipocytokines concentrations. |  |
|---|---|---|---|
| EDSS [median; minimum-maximum] | Leptin [ng/ml] | Adiponectin [ng/ml] | Resistin [ng/ml] |
| INF 1b baseline | 1.0 | 0-2.5 | 14.61 | 6.60-28.99 | 2383.64 | 1620.48-3287.06 | 29.40 | 17.28-37.34 |
| INF 1b 1 month | 1.0 | 0-3.5 | 12.35 | 5.73-31.63 | 2362.09 | 1673.86-2866.10 | 19.32 | 14.97-28.79 |
| INF 1b 6 months | 1.0 | 0-3.0 | 14.70 | 7.89-25.13 | 1318.68 | 8.91-29.75 | 13.90 | 11.05-18.98 |

Table 4: The effects of glatiramer acetate treatment on adipocytokine concentrations.

| Table 4: The effects of glatiramer acetate treatment on adipocytokine concentrations. |  |
|---|---|---|---|
| EDSS | Leptin [ng/ml] | Adiponectin [ng/ml] | Resistin [ng/ml] |
| GA baseline | 1.0 | 0-2.0 | 19.16 ± 14.49 | 1978.21 | 1409.95-3643.83 | 36.61 | 30.16-46.55 |
| GA 1 month | 2.0 | 0-2.2 | 20.62 ± 14.27 | 1647.22 | 1352.15-3782.36 | 36.17 | 28.18-51.55 |
| GA 6 month | 1.0 | 0-2.0 | 14.59 ± 12.32 | 2265.35 | 1374.58-3566.76 | 24.43 | 19.22-28.88 |

We have found that interferon-1b treatment causes a beneficial and time-dependent effect on resistin concentration in RRMS patients. We are not aware of any studies on interferon treatment on resistin concentrations in RRMS patients. Only recently did any experimental study exist in which the stimulation of interferon alpha and beta lead to the decreased expression of leptin, adiponectin, and resistin in adipose tissue [36]. Adiponectin and leptin concentrations were not influenced by interferon treatment in our study. Batocchi et al. suggested that leptin may be a marker of MS activity and its response to therapy, because of a lowering effect interferon treatment has on leptin levels [20]. We have not found such an effect; however, the disability of our MS cohort measured with the EDSS was less severe compared to Batocchi’s group. Thus, the effect of interferon treatment on adipocytokines may depend on disease severity. This suggestion is supported by a report that showed no effect of interferon beta treatment on leptin levels in patients who had secondary progressive multiple sclerosis (SPMS), a beneficial influence on leptin concentrations was observed only in patients who did not have progression in disability [37]. Both interferon beta and glatiramer acetate did not show any effect on adiponectin concentration in our study and such an observation was also reported by Musabak et al. [19]. Moreover, we did not notice an effect of glatiramer acetate on leptin concentration. We have found a beneficial effect of glatiramer acetate on resistin concentration in our RRMS patients. To the best of our knowledge this is the first report on resistin level modulation by glatiramer acetate. This finding may be of particular importance because resistin gene polymorphisms have been suggested to be involved in MS pathogenesis [16].

We did not detect a relationship between EDSS score, localization of demyelinating plaques on MRI scans, or HOMA-IR insulin resistance index and adipocytokine concentrations in RRMS patients treated with first-line immunomodulatory drugs. This can be explained by the low disability in our patients, reflected by their low EDSS scores. As a result, the effect of treatment can only be observed at the molecular level, and not with clinical measures. Similarly, in another study [19], the authors did not find a correlation between adiponectin concentration and EDSS score.
To conclude, we identified resistin as the most important adipocytokine to be associated with RRMS patients. Its concentrations are reduced by first line immunomodulatory treatment of RRMS, which produces a beneficial milieu of inflammatory and metabolic processes. On the other hand, the routine treatment of MS relapse with methylprednisolone induces harmful metabolic and inflammatory effect leading to an increase in leptin levels.

References